CU24123B1 - Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato - Google Patents

Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato

Info

Publication number
CU24123B1
CU24123B1 CU20120147A CU20120147A CU24123B1 CU 24123 B1 CU24123 B1 CU 24123B1 CU 20120147 A CU20120147 A CU 20120147A CU 20120147 A CU20120147 A CU 20120147A CU 24123 B1 CU24123 B1 CU 24123B1
Authority
CU
Cuba
Prior art keywords
amino
fluorofenixi
monohidrate
trifluorometil
carbonil
Prior art date
Application number
CU20120147A
Other languages
English (en)
Other versions
CU20120147A7 (es
Inventor
Juergen Stiehl
Werner Heilmann
Michael Lögers
Joachim Rehse
Michael Gottfried
Saskia Wichmann
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24123(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CU20120147A7 publication Critical patent/CU20120147A7/es
Publication of CU24123B1 publication Critical patent/CU24123B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Containers And Plastic Fillers For Packaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CU20120147A 2010-04-15 2011-04-08 Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato CU24123B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15
PCT/EP2011/055508 WO2011128261A1 (en) 2010-04-15 2011-04-08 Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate

Publications (2)

Publication Number Publication Date
CU20120147A7 CU20120147A7 (es) 2013-01-30
CU24123B1 true CU24123B1 (es) 2015-08-27

Family

ID=44070712

Family Applications (2)

Application Number Title Priority Date Filing Date
CU20120147A CU24123B1 (es) 2010-04-15 2011-04-08 Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato
CU2014000060A CU20140060A7 (es) 2010-04-15 2014-05-26 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato

Family Applications After (1)

Application Number Title Priority Date Filing Date
CU2014000060A CU20140060A7 (es) 2010-04-15 2014-05-26 4-{4-[({[ 4- cloro-3-( trifluorometil) fenil] amino} carbonil) amino]-3- fluorofenoxi}-n-metilpiridina-2- carboxamida y su monohidrato

Country Status (40)

Country Link
US (5) US8748622B2 (es)
EP (1) EP2558448B1 (es)
JP (1) JP5934182B2 (es)
KR (2) KR20170129276A (es)
CN (2) CN103980191A (es)
AR (2) AR081060A1 (es)
AU (1) AU2011240113B2 (es)
BR (1) BR112012026117B1 (es)
CA (1) CA2796238C (es)
CL (1) CL2012002840A1 (es)
CO (1) CO6630136A2 (es)
CR (1) CR20120526A (es)
CU (2) CU24123B1 (es)
DK (1) DK2558448T3 (es)
DO (2) DOP2012000268A (es)
EC (1) ECSP12012234A (es)
ES (1) ES2542610T3 (es)
GT (1) GT201200280A (es)
HK (1) HK1200831A1 (es)
HR (1) HRP20150885T1 (es)
HU (1) HUE026821T2 (es)
IL (2) IL222348B (es)
JO (1) JO3158B1 (es)
MA (1) MA34156B1 (es)
MX (1) MX2012011734A (es)
MY (2) MY177066A (es)
NZ (1) NZ602997A (es)
PE (2) PE20130181A1 (es)
PH (1) PH12012502060A1 (es)
PL (1) PL2558448T3 (es)
PT (1) PT2558448E (es)
RS (1) RS54219B1 (es)
RU (1) RU2581585C2 (es)
SG (2) SG184172A1 (es)
SI (1) SI2558448T1 (es)
TN (1) TN2012000492A1 (es)
TW (2) TWI475992B (es)
UA (1) UA110613C2 (es)
UY (2) UY33290A (es)
WO (1) WO2011128261A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101381454B1 (ko) * 2004-09-29 2014-04-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AR092439A1 (es) 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
MY183969A (en) 2012-09-25 2021-03-17 Bayer Pharma AG Combination of regorafenib and acetylsalicylic acid for treating cancer
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
WO2015049698A2 (en) * 2013-10-04 2015-04-09 Hetero Research Foundation Process for regorafenib
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
US9790185B2 (en) 2014-07-09 2017-10-17 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
SG11201806116SA (en) * 2016-01-18 2018-08-30 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CA3244313A1 (en) 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
WO2021160708A1 (en) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combination of regorafenib and msln-ttc for treating cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ATE345130T1 (de) 2001-12-03 2006-12-15 Bayer Pharmaceuticals Corp Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
PT1580188E (pt) 2002-02-11 2012-01-25 Bayer Healthcare Llc Aril-ureias como inibidores de cinases
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
JP5128948B2 (ja) 2004-08-27 2013-01-23 ニッポネックス インコーポレイテッド 癌の治療のための新規な薬剤組成物
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
NZ554119A (en) 2004-09-29 2010-07-30 Bayer Schering Pharma Ag Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide
KR101381454B1 (ko) 2004-09-29 2014-04-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
WO2007053573A2 (en) 2005-10-31 2007-05-10 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
WO2007059154A2 (en) 2005-11-14 2007-05-24 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2668748A1 (en) * 2006-11-09 2008-05-15 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
WO2008058644A1 (en) * 2006-11-14 2008-05-22 Bayer Schering Pharma Aktiengesellschaft Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
EP2111401B1 (en) 2006-12-20 2011-02-16 Bayer HealthCare, LLC 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino]-3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
CA2675979A1 (en) 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
EP2129376B1 (en) 2007-01-19 2013-07-24 Bayer HealthCare LLC Treatment of cancers with acquired resistance to KIT inhibitors
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
JP5439494B2 (ja) 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
RU2011150619A (ru) 2009-05-15 2013-06-20 Новартис Аг Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EA201300420A1 (ru) 2010-10-01 2013-09-30 Байер Интеллектчуал Проперти Гмбх Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид
EA201400064A1 (ru) 2011-06-28 2014-05-30 Байер Хелфкеэ Ллк Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
US20140235678A1 (en) 2011-06-28 2014-08-21 Bayer Healthcare Llc Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
AR092439A1 (es) 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib

Also Published As

Publication number Publication date
BR112012026117A8 (pt) 2017-12-19
AR081060A1 (es) 2012-06-06
IL253119A0 (en) 2017-08-31
KR101800041B1 (ko) 2017-11-21
CR20120526A (es) 2013-03-11
US9458107B2 (en) 2016-10-04
AU2011240113B2 (en) 2014-12-18
US20170334857A1 (en) 2017-11-23
US8748622B2 (en) 2014-06-10
AR116395A2 (es) 2021-05-05
TW201509415A (zh) 2015-03-16
UY39590A (es) 2022-01-31
RU2581585C2 (ru) 2016-04-20
UY33290A (es) 2011-12-01
EP2558448A1 (en) 2013-02-20
US10822305B2 (en) 2020-11-03
CN103980191A (zh) 2014-08-13
NZ602997A (en) 2014-10-31
PT2558448E (pt) 2015-09-01
SI2558448T1 (sl) 2015-11-30
DOP2016000285A (es) 2016-11-30
WO2011128261A1 (en) 2011-10-20
TWI475992B (zh) 2015-03-11
EP2558448B1 (en) 2015-05-20
JO3158B1 (ar) 2017-09-20
JP2013523851A (ja) 2013-06-17
MX2012011734A (es) 2012-12-17
UA110613C2 (uk) 2016-01-25
BR112012026117A2 (pt) 2015-09-08
MY177066A (en) 2020-09-03
CA2796238C (en) 2019-12-31
MY162359A (en) 2017-06-15
JP5934182B2 (ja) 2016-06-15
RS54219B1 (sr) 2015-12-31
TN2012000492A1 (en) 2014-04-01
US20170057918A1 (en) 2017-03-02
PH12012502060A1 (en) 2013-02-04
SG10201501221UA (en) 2015-04-29
KR20170129276A (ko) 2017-11-24
SG184172A1 (en) 2012-11-29
CO6630136A2 (es) 2013-03-01
CN102947271B (zh) 2016-11-09
IL222348A0 (en) 2012-12-31
GT201200280A (es) 2014-07-23
IL222348B (en) 2018-08-30
BR112012026117B1 (pt) 2022-08-30
PE20130181A1 (es) 2013-02-23
IL253119B (en) 2018-03-29
US20130116442A1 (en) 2013-05-09
HK1200831A1 (en) 2015-08-14
PE20160838A1 (es) 2016-09-24
CL2012002840A1 (es) 2013-01-18
ECSP12012234A (es) 2012-11-30
ES2542610T3 (es) 2015-08-07
DK2558448T3 (en) 2015-08-24
HUE026821T2 (en) 2016-07-28
TWI539951B (zh) 2016-07-01
CU20120147A7 (es) 2013-01-30
HRP20150885T1 (hr) 2015-10-09
US20190144391A1 (en) 2019-05-16
RU2012148386A (ru) 2014-05-20
AU2011240113A1 (en) 2012-10-11
CA2796238A1 (en) 2011-10-20
MA34156B1 (fr) 2013-04-03
CU20140060A7 (es) 2014-10-02
CN102947271A (zh) 2013-02-27
PL2558448T3 (pl) 2015-10-30
DOP2012000268A (es) 2012-12-15
US20140221661A1 (en) 2014-08-07
KR20130061670A (ko) 2013-06-11
TW201204356A (en) 2012-02-01

Similar Documents

Publication Publication Date Title
CU24123B1 (es) Procedimiento para la preparación de 4-{ 4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenixi}-n-metilpiridina-2-carboxamida y su monohidrato
HUS1900012I1 (hu) Vegyületek és készítmények protein-kináz inhibitorokként
KR101967085B9 (ko) 건조 및 안정한 지혈 조성물의 제조 방법
IL244000A0 (en) Anti-fap antibodies and methods of use
LT3040424T (lt) Modifikuoti baltymai ir jų gavimo ir panaudojimo būdai
PT2170279T (pt) Métodos para produção de suspensão de aripiprazole e formulação liofilizada
IL223118A (en) Medicament inhaler and method for its assembly
BR112012031446A2 (pt) componentes e métodos para implantes
HRP20170961T1 (hr) Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata
DK3333188T3 (da) Anti-NGF-antistoffer og deres anvendelse
DK3663399T3 (da) Modificerede factor IX-polypeptider og anvendelser deraf
DK2547771T3 (da) Fremstilling af proteiner og polypeptider
BR112013010651A2 (pt) piso de madeira e método para fabricar piso de madeira
BRPI0921320A2 (pt) composições de anticorpo estáveis e métodos para estabilizar os mesmos
IL222961B (en) DNA binding proteins and their uses
PL2575778T3 (pl) KOMPOZYCJE FARMACEUTYCZNE KOKRYSZTAŁÓW TRAMADOLU i KOKSYBÓW
DK2555629T3 (da) Proteinprodukt og fremgangsmåde til fremstilling af injicérbart proteinprodukt
HRP20150071T1 (xx) Agomelatin hidroklorid hidrat i njegova priprava
ES2707773T8 (es) Compuesto para juntas premezclado y de fraguado instantáneo
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
CO6781494A2 (es) Composición lubricante y método para su preparación
IT1399926B1 (it) Procedimento per la produzione di formaggio in polvere almeno parzialmente essiccato
HRP20160918T1 (hr) Postupak pripreme 6-klor-2,3,4,9-tetrahidro-1h-karbazol-1-karboksamida i njegovih prekursora
BR112012029669A2 (pt) composição e método
EP2734543A4 (en) LACTOFERRIN FRAGMENTS AND THEIR USE

Legal Events

Date Code Title Description
FG Grant of patent